Mylan Receives Voluntary License Rights to Gilead's HIV/AIDS Pipeline Products in Developing World

Mylan Inc. MYL today announced an expanded licensing agreement between Gilead Sciences Inc. and Mylan's Matrix Laboratories Limited. Matrix has licensed the rights to produce and market generic versions of three Gilead HIV/AIDS therapies, if and when they receive regulatory approval. The Gilead products, which are currently in late-stage clinical development, include: Elvitegravir, an investigational integrase inhibitor; Cobicistat, an investigational antiretroviral boosting agent; and the "Quad," a once-daily, single-tablet combination of four separate Gilead medicines.